[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637711":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":35,"responsibleParty":46,"collaborators":48,"id":52,"slug":10,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":10,"overallStatus":70,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"NYU Langone Health","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"IBD Patients Initiating Guselkumab",null,"Individuals with confirmed clinical SpA diagnosis who are initiating guselkumab as standard care for CD or UC will take surveys every 3 months over a 1-year timeframe.",[13],"Drug: Guselkumab",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Guselkumab","Guselkumab intravenous or subcutaneous induction.",[9],[21],"Tremfya",[23],{"name":24,"affiliation":5,"role":25},"David Hudesman, MD","PRINCIPAL_INVESTIGATOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"Nathasha Melukkaran","CONTACT","646-754-3417","Nathasha.melukkaran@nyulangone.org",{"name":33,"role":29,"phone":30,"phoneExt":10,"email":34},"Peik Sean Chong","Peiksean.chong@nyulangone.org",[36],{"facility":5,"status":10,"city":37,"state":37,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":10},"New York","10016","United States",{"type":41,"coordinates":42},"Point",[43,44],-74.00597,40.71427,{"lat":44,"lon":43},{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[49],{"name":50,"class":51},"Janssen Scientific Affairs, LLC","INDUSTRY","100637711",false,"NCT07602517","Guselkumab for Overlap Inflammatory Bowel Disease and Spondyloarthritis","GLOBE-SpA - GuseLkumab for Overlap Inflammatory Bowel DiseasE and Spondyloarthritis","GLOBE-SpA","Inclusion Criteria:\n\n* Confirmed diagnosis of Crohn's disease or Ulcerative Colitis disease based on confirmatory colonoscopy with biopsies, or if small bowel only, MRE with corresponding history\n* Age between 18 to 75 years old\n* Inflammatory bowel disease unclassified (IBD-U) subjects are eligible for inclusion if based on investigator assessment, the subject meets criteria for IBD-U, defined as chronic inflammatory bowel disease with overlapping features of Crohn's disease or ulcerative colitis\n* Initiating Guselkumab therapy in the next 30 days\n* Bio-naïve or bio-experienced\\* to ≤3 mechanisms of action \\*Defined as prior exposure or failure, as defined by inadequate efficacy or intolerance\n\nExclusion Criteria:\n\n* Unable to provide consent for participation\n* Known SpA diagnosis, prior to screening\n* Has started Guselkumab therapy\n* Prior exposure to IL-23 therapy (like Mirikizumab, Ustekinumab, etc.)\n* Prior exposure to TB, active or currently undergoing treatment for latent TB\n* Pregnancy as some pregnancy symptoms could be mistaken for SpA symptoms\n* Prior exposure to combination advanced biologic therapies","ALL","18 Years","75 Years",{"count":63,"type":64},75,"ESTIMATED","OBSERVATIONAL","This is an observational study of a prospective cohort of guselkumab-initiating Crohn's Disease (CD) and Ulcerative Colitis (UC) patients to identify new or incident spondyloarthritis. This study will include adult patients aged 18-75 with IBD who are undergoing guselkumab intravenous or subcutaneous induction over a 1-year timeframe.",[68,69],"Spondyloarthritis","Inflammatory Bowel Diseases","NOT_YET_RECRUITING","2026-05-15",{"date":73,"type":74},"2026-05-22","ACTUAL",{"date":76,"type":64},"2026-05-20",{"date":78,"type":64},"2029-05-20",{"name":5,"class":6},1]